CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Published:2018-07 Issue:1 Volume:34 Page:9-20
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Klein Mary E.,Kovatcheva Marta,Davis Lara E.,Tap William D.,Koff Andrew

Funder

NIH

NCI

Maloris Foundation

Cycle for Survival

Sarcoma Foundation of America

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference70 articles.

1. A complex secretory program orchestrated by the inflammasome controls paracrine senescence;Acosta;Nat. Cell Biol.,2013

2. Control of senescence by CXCR2 and its ligands;Acosta;Cell Cycle,2008

3. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells;Anders;Cancer Cell,2011

4. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat. Rev. Drug Discov.,2015

5. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6;Baughn;Cancer Res.,2006

Cited by 274 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The paradox of senescent-marker positive cancer cells: challenges and opportunities;npj Aging;2024-09-14

2. Dronedarone inhibits the proliferation of esophageal squamous cell carcinoma through the CDK4/CDK6-RB1 axis in vitro and in vivo;Frontiers of Medicine;2024-09-13

3. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-12

4. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

5. Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark;Nature Communications;2024-08-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3